Chemoradiotherapy with 3-weekly CDDP 80 mg/m2 for head and neck squamous cell carcinoma: 5-year survival data from a phase 2 study

Chemoradiotherapy with 3-weekly CDDP 80 mg/m2 for head and neck squamous cell carcinoma: 5-year survival data from a phase 2 study

ObjectiveThe global standard for chemoradiation therapy (CCRT) for head and neck squamous cell carcinoma is cisplatin 100 mg/m2 administered once every three weeks, although cisplatin 80 mg/m2 is also widely used as an alternative treatment to reduce adverse events in Japan. We aimed to assess the l...

Full description

Bibliographic Details
Main Authors: Kohei Otaki, Takeshi Takahashi, Ryoko Tanaka, Kohei Saijo, Jo Omata, Yusuke Yokoyama, Ryusuke Shodo, Yushi Ueki, Keisuke Yamazaki, Hisayuki Ota, Takafumi Togashi, Nao Takahashi, Ryuichi Okabe, Hiroshi Matsuyama, Arata Horii
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Surgery
Subjects:
head and neck cancer
squamous cell carcinoma
chemoradiotherapy
3-weekly CDDP 80 mg/m 2
5-year survival data
late adverse events
Online Access:https://www.frontiersin.org/articles/10.3389/fsurg.2022.1035349/full

Internet

https://www.frontiersin.org/articles/10.3389/fsurg.2022.1035349/full

Similar Items